A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by National University Hospital, Singapore.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT00718211
First received: July 15, 2008
Last updated: July 18, 2008
Last verified: July 2008

July 15, 2008
July 18, 2008
May 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00718211 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore.

To review the characteristics and treatment of gastrointestinal tumours at the two tertiary centres in Singapore

A retrospective clinical records review of patients diagnosed with gastrointestinal stromal tumour (GIST) in the two tertiary centres in Singapore i.e. Singapore General Hospital and National University Hospital.

Gastrointestinal tumours are the most common soft-tissue tumours of the gastrointestinal tracts. Remarkable progress has been made during the last several years in the diagnosis and treatment of GIST. Understanding of the molecular pathogenesis of GIST which is linked to deregulated KIT tyrosine-kinase activity has improved diagnosis, such that GIST is now more frequently and specifically identified. More importantly, systemic tyrosine kinase inhibitor, imatinib, has been used successfully in the treatment of GIST patients with advanced or unresectable disease.

GIST has been reviewed in the Western literature but there is a lack of Asian data. The review will help us to better understand the disease in our population.Furthermore we will also examine several unresolved issues in the Western literature by looking into our local data. These include required duration of imatinib therapy, role of imatinib in the adjuvant setting (application of chemotherapy after macroscopically complete removal of tumour) and role of combination therapies.

The medical records of all patients diagnosed with the disease at the two centres will be reviewed.

Analysis of the results aims to:

  1. to compare the characteristics of the GIST (epidemiology, site, morphology, immunohistochemistry profile) in our centres compared to the well-published literature.
  2. to compare the treatment regimen and results of our centres compared to others
  3. to review the role of chemotherapy in the adjuvant settings in the centres.
Observational
Not Provided
Not Provided
Not Provided
Probability Sample

To review medical records of all patients diagnosed with the disease at the two specified centres.

The medical records will be obtained through both paper and electronic medical systems.

All data will be contained in a password secured database and will be securely located behind institutional firewalls.

Gastrointestinal Stromal Tumors
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Patients diagnosed with Gastrointestinal stromal tumor.
Both
Not Provided
No
Contact: Ross Andrew Soo, MBBS 65-6772-4624 Ross_Soo@nuh.com.sg
Singapore
 
NCT00718211
GA01/12/06
Not Provided
Not Provided
National University Hospital, Singapore
Not Provided
Principal Investigator: Ross Andrew Soo, MBBS National University Hospital, Singapore
National University Hospital, Singapore
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP